- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 13
The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of November 13.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 13.
Number 5: Intragovernmental organization The South Centre has released a paper that calls on regulatory bodies to approve “biological generics” rather than biosimilars.
Number 4: At the SMi Biosimilars North America 2017 conference, a Mylan executive warned that reference product sponsors may be involved in a “whisper campaign” against biosimilars.
Number 3: A recent review identified patient-, disease-, and treatment-related factors that may predict response to anti—tumor necrosis factor therapies.
Number 2: Contributor Sonia T. Oskouei breaks down the key facts that biosimilar stakeholders need to know about CMS’ recent change in biosimilar reimbursement policy.
Number 1: Two major biosimilar patent litigation cases came to a close in recent days, with the ruling Amgen v Apotex upheld in an appellate court, and with Janssen dropping its suit against biosimilar developer Samsung Bioepis.
To read all of these articles and more, visit centerforbiosimilars.com.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
